TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02495220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB dexmedetomidine bupivacaine block
Description: SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous dexmedetomidine
Description: received 1µ/kg IV dexmedetomidine
Study: NCT02762279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: esophageal and pleural pressure measurement
Description: Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
Study: NCT02882490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Therapy
Study: NCT02895503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participate in yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support Group Therapy
Description: Participate in emotional support group therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-L
Description: This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACT-L
Description: This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, \& Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary function test
Description: The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary function test
Description: The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
Study: NCT02920424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56022473
Description: Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56022473
Description: Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo.
Study: NCT01130051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg intact tablet taken by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg tablet
Description: One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
Study: NCT03057002

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized 13C-Pyruvate
Description: All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hyperpolarized 13C-Pyruvate
Description: All subjects will be observed for myocardial hyperpolarized \[1-13C\]pyruvate flux during magnetic resonance spectroscopic imaging.
Study: NCT04687813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with the same appearance as FTP-198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with the same appearance as FTP-198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is a tablet with the same appearance as FTP-198
Study: NCT02848950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Supplementation of the study group with Metformin till the day of pregnancy confirmation
Study: NCT02807649

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Nutrilite® Low dose
Description: Two tablets consume daily with meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: Nutrilite® High dose
Description: Two tablets consume daily with meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Two tablets consume daily with meal.
Study: NCT00851123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement therapy
Description: Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-specific bimanual training
Description: Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
Study: NCT03715088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Intervention
Description: Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Intervention
Description: Participants will perform 10 different resistance exercises consisting of three sets of 8-10 repetitions, at 80% of 1-RM, separated by 60-second rest intervals between sets. This exercise protocol was chosen based on literature that suggests that the protocol and intensity do not enhance mitochondria biogenesis. Also, it was well tolerated by obese and older individuals.
Study: NCT02747953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilotrif
Description: 50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
Study: NCT06363669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-ingredient pre-workout dietary supplement (caffeine-based)
Description: The participants performed the exercise twice, in random order: as a control test and after supplement administration. The acute effects of MIPS supplementation (beta-alanine 3000 mg, taurine 1000 mg, caffeine 290 mg, L-tyrosine 125 mg, and cayenne pepper extract (Capsicum annuum L.) 4.2 mg (of which 8% capsaicin)) on aerobic and anaerobic performance were evaluated in untrained men
Study: NCT01335009

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MORAb-004 (monoclonal antibody)
Description: Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MORAb-004 (monoclonal antibody)
Description: Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs or clinical or symptomatic progression as suggested by an investigator.
Study: NCT04196738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation strategy
Description: Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventilation strategy
Description: Patients are ventilated in randomised order with three different ventilation strategies: volume assist control (constant flow), Dual Mode or Airway Pressure Released Ventilation
Study: NCT01169220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Go-Lytely
Description: Bowel cleansing agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Go Lytely
Description: Bowel cleansing agent
Study: NCT02954939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF-MMF
Description: Class III/IV+/-V lupus nephritis patients to receive PRED+MMF

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CTX-AZA
Description: Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
Study: NCT03405597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercial Hepatitis B vaccine
Description: Commercial Hepatitis B vaccine (Engerix B) 20 microgram subcutaneous injection at month 0, 1, 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
Study: NCT06734806

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic Imaging and Digital STL Analysis
Description: This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic Imaging and Digital STL Analysis
Description: This study utilizes radiographic imaging (bitewing radiographs) and digital analysis of archived STL files to evaluate the clinical performance of endocrown and overlay restorations. The STL files are processed using Materialise 3-matic software to calculate cemented surface areas. Radiographic imaging assesses the presence of secondary caries or other failures. These diagnostic methods provide quantitative and visual data to evaluate long-term outcomes of the restorations.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDI Criteria Evaluation and Plaque Index Measurement
Description: This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.

Intervention type: DIAGNOSTIC_TEST
Intervention: FDI Criteria Evaluation and Plaque Index Measurement
Description: This intervention includes the evaluation of dental restorations using modified FDI criteria, assessed on a 5-point Likert scale that measures aesthetic, functional, and biological outcomes. Additionally, oral hygiene is assessed through the measurement of the plaque index, with a mean score calculated for each participant. The use of both FDI-based Likert scoring and plaque index measurements allows for a detailed evaluation of restoration performance and oral health status, combining subjective patient-reported outcomes with objective clinical metrics.
Study: NCT02901925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABY-029
Description: Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
Study: NCT01264653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adrenalin
Description: adrenalin 0.01%
Study: NCT03405597

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: HBsAg, HBsAb test Ultrasound upper abdomen every 6 months
Study: NCT03116412

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT or PET scans
Description: Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
Study: NCT02428010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMVR Implant
Description: Implantation of the Twelve TMVR System
Study: NCT05762523

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - оnce at a dose of 10⁶ PFU
Description: 15 volunteers vaccinated once intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - once at a dose of 10⁷ PFU
Description: 15 volunteers vaccinated once intradermally at a dose of 10⁷ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAC∆6 vaccine - twice at a dose of 10⁶ PFU
Description: 15 volunteers vaccinated twice spaced 28 days apart, intradermally at a dose of 10⁶ PFU (0.2 ml) of the VAC∆6 vaccine in the outer surface of the shoulder 8-10 cm below the shoulder joint

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live smallpox vaccine (Smallpox vaccine) + The OspaVir® inactivated smallpox vaccine
Description: 15 volunteers vaccinated by the two-step vaccination method: Step 1 - the first vaccination once subcutaneously with 1 dose (0.5 ml) of the inactivated smallpox vaccine OspaVir® in the area of the left shoulder 8-10 cm below the shoulder joint; Step 2 - the second vaccination once by the method of multiple puncture into the outer surface of the shoulder 8-10 cm below the shoulder joint with a live smallpox vaccine at a dose of 1x 106 PFU 7 days following the first vaccination with OspaVir®.
Study: NCT00332839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin A (CsA)
Description: The dose was based on the participants' blood level of C0h (80-150 ng/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: The dose was based on the participants' blood level of C0h (5-10 ng/ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated - Mycophenolate Sodium (EC-MPS)
Description: The dose was ≥ 720 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric Coated - Mycophenolate Sodium (EC-MPS)
Description: The dose was ≥ 720 mg/day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids were given according to local standard and/or the Investigators' discretion.
Study: NCT03465631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART Glove system with tDCS
Description: combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SMART Glove system with sham-tDCS
Description: combined bilateral tDCS and VR-based therapy on distal upper extremity training in patients with stroke.
Study: NCT00112931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No treatment
Study: NCT03725514

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional Blood Clot Technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRF
Description: Platelet Rich Fibrin Technique
Study: NCT04485273

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Airway
Description: Capnography connected to laryngeal mask airway is introduced after adequate jaw relaxation and oral airway tolerance; its size is chosen according to the body weight of the child.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane in air/oxygen mixture of 40% is titrated to achieve adequate depth of anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subtenon's Block
Description: Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subtenon's Block
Description: Subtenon's block is performed in the eye undergoing surgery under sterile conditions where a 19-gauge curved blunt metallic cannula (25 mm) is inserted into sub-tenon's space.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic Solution and Dexmedetomedine
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Local Anesthetic Solution
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
Study: NCT01283230

Intervention type: DEVICE
Intervention: Acoustic radiation force impulse imaging
Description: Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.

Intervention type: DEVICE
Intervention: Acoustic radiation force impulse imaging
Description: Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
Study: NCT02760953

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
Study: NCT03004937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Medicine Hearing Loss Best Practice Alert
Description: A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).